ReviewPharmaceuticals (Basel, Switzerland)2023
Ionic Liquids as Tools to Incorporate Pharmaceutical Ingredients into Biopolymer-Based Drug Delivery Systems.
Review in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Ionic Liquid-Enabled Drug Delivery Systems: Benefits, Limitations, and Future Perspectives.Pharmaceutics · 2026Review
- CoScientific reports · 2025Article
- Editorial: Micro-nano-materials for drug delivery, disease diagnosis, and therapeutic treatment.Frontiers in bioengineering and biotechnology · 2025Article
- A review on oral novel delivery systems of insulin through the novel delivery system formulations: A review.SAGE open medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This mini-review focuses on the various roles that ionic liquids (ILs) play in the development and applications of biopolymer-based drug delivery systems (DDSs). Biopolymers are particularly attractive as drug delivery matrices due to their biocompatibility, low immunogenicity, biodegradability, and strength, whereas ILs can assist the formation of drug delivery systems. In this work, we showcase the different strategies that were explored using ILs in biopolymer-based DDSs, including impregnation of active pharmaceutical ingredients (APIs)-ILs into biopolymeric materials, employment of the ILs to simplify the process of making the biopolymer-based DDSs, and using the ILs either as dopants or as anchoring agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.